Acrobiosystems Co

Acrobiosystems Co Gross Margin

The Gross Margin of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 91.16 %. In the previous year, Gross Margin was 90.93 % — a change of 0.24% (higher).

Gross Margin

91.16 %

YoY

0.24%

Last updated:

Gross Margin of Acrobiosystems Co is 2025 91.16 % . Gross Margin of Acrobiosystems Co was 2024 90.93 % . It decreases by 0.24% higher compared to the previous year.

Acrobiosystems Co's gross margin stands at 91.2%, down from 92.6% several years earlier.

The Acrobiosystems Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
87.83 CNY
Jan 1, 2019
88.46 CNY
Jan 1, 2020
91.91 CNY
Jan 1, 2021
92.57 CNY
Jan 1, 2022
92.51 CNY
Jan 1, 2023
91.26 CNY
Jan 1, 2024
90.93 CNY
Jan 1, 2025
91.16 CNY
The Acrobiosystems Co Gross Margin history
YEARGross MarginYoY
91.16 %+0.24%
90.93 %-0.36%
91.26 %-1.34%
92.51 %-0.06%
92.57 %+0.72%
91.91 %+3.89%
88.46 %+0.72%
87.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Gross Margin of Acrobiosystems Co is 91.16 % in 2025.

Gross Margin of Acrobiosystems Co changed from 90.93 % to 91.16 %, representing a 0.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co